BWV

iPath CBOE S&P 500 BuyWrite ETN [BWV] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BWV Stock Summary

In the News

BWV Financial details

Company Rating
-
Market Cap
3.41M
Income
-18.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
09 Mar 2024
P/E
-0.17
Forward P/E
-
PEG
-0.01
P/S
-
P/B
0.31
P/C
-
P/FCF
-0.28
Quick Ratio
0.43
Current Ratio
0.54
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.18
EPS next Y
-
EPS next Q
-
EPS this Y
248.39%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-27.91%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-65%
ROE
-111%
ROC
-1.68%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.1601-1.95
52W High
-
52W Low
-
RSI
-
Rel Volume
0.29
Avg Volume
435.53K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
EMBASSY.NS
BRH.DE
AMZ.DE
CMC.DE
M&M.NS
Same Sector
084990.KQ
TRVI
AMRN
QBIO
EYPT
Check Those
BGI
INC-UN.TO
NODL.OL
1477.TW
GAQ-UN
Similar Market Cap
AIIQ
INV.L
HSDT
PDV.TO
SYTA

Company Profile

Healthcare Biotechnology
  • Volume Average 435.53K
  • Market Capitalization 3.41M
  • Employee 12
  • CEO Dr. Neil J. Campbell MA, MBA
  • Headquarters Cincinnati,OH,US
  • IPO Date 2022-02-18
  • Website https://www.bluewatervaccines.com

Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.